Recombinant human insulin-like growth factor I (rhIGF-I) for the treatment of amyotrophic lateral sclerosis/motor neuron disease: Cochrane systematic review

Recombinant human insulin-like growth factor I (rhIGF-I) for the treatment of amyotrophic lateral sclerosis/motor neuron disease: Cochrane systematic review is a topic covered in the Cochrane Abstracts.

To view the entire topic, please sign in or purchase a subscription.

Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics:

20 mcg versus >20 mcg estrogen combined oral contraceptives for contraception

"Snowball fingers" - Image

Botulinum toxin for the treatment of strabismus: Cochrane systematic review

ACC/AHA: Fewer patients require prophylaxis for endocarditis

Citation

"Recombinant Human Insulin-like Growth Factor I (rhIGF-I) for the Treatment of Amyotrophic Lateral Sclerosis/motor Neuron Disease: Cochrane Systematic Review." Cochrane Abstracts, Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/433263/all/Recombinant_human_insulin_like_growth_factor_I__rhIGF_I__for_the_treatment_of_amyotrophic_lateral_sclerosis_motor_neuron_disease:_Cochrane_systematic_review. Accessed 18 January 2019.

Recombinant human insulin-like growth factor I (rhIGF-I) for the treatment of amyotrophic lateral sclerosis/motor neuron disease: Cochrane systematic review. Cochrane Abstracts. https://evidence.unboundmedicine.com/evidence/view/Cochrane/433263/all/Recombinant_human_insulin_like_growth_factor_I__rhIGF_I__for_the_treatment_of_amyotrophic_lateral_sclerosis_motor_neuron_disease:_Cochrane_systematic_review. Accessed January 18, 2019.

Recombinant human insulin-like growth factor I (rhIGF-I) for the treatment of amyotrophic lateral sclerosis/motor neuron disease: Cochrane systematic review. In Cochrane Abstracts. Available from https://evidence.unboundmedicine.com/evidence/view/Cochrane/433263/all/Recombinant_human_insulin_like_growth_factor_I__rhIGF_I__for_the_treatment_of_amyotrophic_lateral_sclerosis_motor_neuron_disease:_Cochrane_systematic_review

Recombinant Human Insulin-like Growth Factor I (rhIGF-I) for the Treatment of Amyotrophic Lateral Sclerosis/motor Neuron Disease: Cochrane Systematic Review [Internet]. In: Cochrane Abstracts. [cited 2019 January 18]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/433263/all/Recombinant_human_insulin_like_growth_factor_I__rhIGF_I__for_the_treatment_of_amyotrophic_lateral_sclerosis_motor_neuron_disease:_Cochrane_systematic_review

* When formatting your citation, note that all book, journal, and database titles should be italicized* Article titles in AMA citation format should be in sentence-case

TY - ELEC T1 - Recombinant human insulin-like growth factor I (rhIGF-I) for the treatment of amyotrophic lateral sclerosis/motor neuron disease: Cochrane systematic review ID - 433263 BT - Cochrane Abstracts UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/433263/all/Recombinant_human_insulin_like_growth_factor_I__rhIGF_I__for_the_treatment_of_amyotrophic_lateral_sclerosis_motor_neuron_disease:_Cochrane_systematic_review DB - Evidence Central DP - Unbound Medicine ER -